Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
ZolgensmaⓇ sales now predominantly incident patient population
C Ezolgensma K KL
Sales evolution
USD m
Ex-US
Both US and ex-US market now mainly incident patient population
US
375
379
363
342
319 315
◉
YTD double digit growth in incident patients treated
319
◉
2500+ patients treated worldwide¹
254
249
256
224 250
200
209
220
◉
148
106
119
126
106
118
113
123
99
Q4
Q1
Q2
Q3
Q4
Q1
Q2
2020
2021
2022
1. Across clinical trials, managed access programs and in the commercial setting.
9 Investor Relations | Q3 2022 Results
3
Q3
Future growth drivers
☐
☐
Foundational treatment for SMA type 1 newborns
Now approved in 45 countries with access pathways in place in 30+
-
Access negotiations ongoing in 10+ countries (e.g. Brazil, Argentina)
Efforts ongoing to increase newborn screening (35% in Europe; 98% in US)
IT data: STEER enrolling continues; STRENGTH to start in Q4 2022
NOVARTIS | Reimagining MedicineView entire presentation